Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Sarcoma 5Unspecified Adult Solid Tumor, Protocol Specific 4Sarcoma, Kaposi 4Rectal Neoplasms 4Colonic Neoplasms 4Skin Neoplasms 3Colorectal Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Oligodendroglioma 2Melanoma 2Head and Neck Neoplasms 2HIV Infections 2Central Nervous System Neoplasms 2Carcinoma, Renal Cell 2Astrocytoma 2AIDS-related Kaposi sarcoma 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solitary Fibrous Tumor, Pleural 1Salivary Gland Neoplasms 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Optic Nerve Glioma 1Neoplasms, Unknown Primary 1Neoplasms, Plasma Cell 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1

Interventions

Cytarabine 561Azacitidine 385venetoclax 311Cyclophosphamide 289fludarabine 246fludarabine phosphate 229Decitabine 187Busulfan 176Daunorubicin 155Idarubicin 151Peripheral Blood Stem Cell Transplantation 138Mycophenolic Acid 134Filgrastim 134Whole-Body Irradiation 133Tacrolimus 125Granulocyte Colony-Stimulating Factor 124Etoposide 117Mitoxantrone 103Methotrexate 103Melphalan 103Cyclosporine 101Antilymphocyte Serum 85Gemtuzumab 84Clofarabine 84Specimen Handling 73Injections 69Stem Cell Transplantation 64Biopsy 57CPX-351 56Thiotepa 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × Semaxinib × Clear all
NCT00005942 2013-01-23

Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy

National Cancer Institute (NCI)

Phase 1/2 Completed
37 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡